drugset

drugset / Trial / NCT05456529

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

NCT05456529 ↗

Phase 3 Completed 103 enrolled Incyte Corporation

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).

Timeline

Start: 2022-09-01
Primary completion: 2024-05-17
Completion: 2024-05-17

Publications

Joyce JC, Hong HC, Siri DD, Toth D, Kallender H, Kuo Y, Stefani-Hunyady D, Papp KA. Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study. Am J Clin Dermatol. 2026 May 27. doi: 10.1007/s40257-026-01043-0. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	1.5 %	—

Indications